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compared to the anticoagulants it had the highest incremental net monetary benefit 
compared with warfarin; £596 (£-6,494 to £4,524). This was due to the low cost and 
risk of adverse events of aspirin. All other comparators had a negative incremental 
net monetary benefit compared with warfarin. ConClusions: For acute treatment, 
apixaban had the highest probability (57%) of being cost-effective at a willingness to 
pay threshold of £20,000 for acute treatment. Novel oral anticoagulants are unlikely 
to be cost-effective for long term use in secondary prevention.
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objeCtives: Worldwide, stroke is the third most common cause of death in devel-
oped countries with declining death rates. In Austria the incidence rate of stroke 
is 2.1 – 2.3 per thousand annually. Cerebrolysin prevents acute neuronal damage 
and accelerates recovery after stroke. The purpose of this analysis was to deter-
mine costs of stroke for Austria in general and to estimate the cost-effectiveness 
of Cerebrolysin in combination with alteplase compared to alteplase alone. The 
analysis should assess health economic advantages in the acute care due to a faster 
improvement in neurological impairment and for rehabilitation in early post-acute 
phase and quantify the correlated reduced resource use in the health care and 
social system. Methods: A Markov-model was developed based on the mRS 
states 90 days after stroke to simulate consequences over a 10-year time-horizon. 
Consequences include recurrent stoke, deteriorated mRS, death due to recurrent 
stroke or other reasons. Health benefits were measured in quality-adjusted life years 
(QALYs) and life years (LYs). Monte-Carlo-simulation accounted for uncertainty. 
Probabilities were derived from RCTs and open-label studies; direct costs (2014) 
were derived from published sources from the payer’s perspective. QALYs, life years 
and costs were projected over a 10 year time-horizon. Costs and outcomes were 
discounted according to the national guidelines Results: Austrian costs associated 
with Cerebrolysin amount to € 61,468.67 and generate 3.77 QALYs and 6.70 LYs. Costs 
without Cerebrolysin amount to € 62,257.88, achieve 3.75 QALYs and 6.70 LYs. The 
treatment strategy with Cerebrolysin dominates the strategy without Cerebrolysin. 
Assessing the disaggregated costs it becomes apparent that costs savings are due to 
lower acute stroke costs (€ -493.29) and nursing-home costs mainly after first stroke 
(€ -250.88). ConClusions: From a health economic perspective, Cerebrolysin is a 
cost-effective therapy; it mainly reduces event costs due to early remobilization 
and, in addition, rehabilitation and nursing-home cost.
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objeCtives: A novel pharmacist guided pharmacogenetic service (PGx) for patients 
newly started on warfarin has been implemented at the University of Illinois 
Hospital & Health Science System (UI-Health). Although the PGx service was found 
to be more effective in reducing bleeding and thrombosis related hospitalizations 
at 90 days post warfarin initiation compared to usual care, the cost of the genotype 
test and the PGx consult service warrants economic evaluation beyond 90-days 
of follow-up. The objective of this study was to evaluate the long-term cost-effec-
tiveness of this novel pharmacist guided warfarin PGx service compared to usual 
care. Methods: A cost-effectiveness model was developed in TreeAge Pro 2014, 
Williamstown, MA, USA. Patients in either the PGx or the usual care cohort followed 
by UI-health were included as comparators and costs and QALYs were estimated 
over a 5 year horizon. Warfarin related (i.e., bleeding or thrombosis) readmissions 
at 30 and 90 days were modeled in a decision tree. Patients in the model without 
a fatal event within 90 days transitioned to a Markov model with a 3-month cycle. 
For patients with venous thromboembolism, the Markov states included well, post 
intracranial hemorrhage (ICH), post thrombotic syndrome, and dead, whereas those 
with atrial fibrillation included well, post ICH, post stroke, post myocardial infarc-
tion and dead. Utilities, cost inputs and transition probabilities were taken from the 
literature and an annual 3% discount rate was used. Results: At 5 years, patients 
managed by the PGx service had expected costs of $7412 and gains of 4.41 QALYs 
whereas those who received usual care had expected costs of $7926 and gains of 
4.39 QALYs. ConClusions: A novel pharmacist guided warfarin pharmacogenetic 
service was projected to be cost-saving and to result in similar or higher QALYs by 
reducing hospitalizations due to warfarin related adverse events.
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objeCtives: To assess the cost-effectiveness of edoxaban versus standard ther-
apy (low molecular weight heparin overlapped and followed by acenocoumarol) 
in patients with venous thromboembolism (VTE), including deep vein thrombosis 
(DVT) and pulmonary embolism (PE). Methods: A Markov model was developed 
to describe the management and consequences of VTE for Spain. We defined a 
cycle’s length of 2 weeks and different health states to simulate the natural history 
of VTE patients after suffering DVT and/or PE. Patients were treated with edoxaban 
or standard therapy for 3, 6 and 12 months, 12 month treatment period being our 
base case scenario. We used the HOKUSAI study and related literature to obtain 
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objeCtives: To evaluate the cost-effectiveness of using levosimendan compared 
with dobutamine, in the perioperative treatment of patients undergoing cardiac 
surgery who require inotropic support. Methods: A two-part Markov model was 
designed to simulate health state transitions of patients undergoing cardiac sur-
gery, and estimate the short- and long-term health benefits of treatment. Hospital 
length of stay (LOS), mortality, medication and adverse events were key clinical 
and cost inputs. Treatment cost-effectiveness was evaluated in terms of costs, 
incremental cost per Life Years (LYs), and incremental cost per Quality-Adjusted 
Life Years (QALYs) gained within the German healthcare system. Drug prices were 
calculated from the German Drug Directory (€ /2014) and published literature, with 
a 3% yearly discount rate applied. The base case analysis was for a one year time 
horizon. Results: The use of levosimendan versus dobutamine was associated 
with cost savings of € 4787 per patient from the German hospital perspective. These 
cost savings were due to reduced adverse events and shorter hospital LOS, lead-
ing to increased bed capacity and hospital revenue. Excluding revenue gains, the 
incremental cost per LY was € 9115 and incremental cost per QALY was € 11,919 
for levosimendan versus dobutamine. Levosimendan was 95% to 100% likely to 
be cost-effective at a willingness to pay threshold of € 20,000 to € 40,000 per QALY. 
Probabilistic sensitivity analyses demonstrated that results were robust to param-
eter changes. ConClusions: The use of levosimendan in patients undergoing 
cardiac surgery who require inotropic support is cost-effective and potentially 
cost-saving compared with dobutamine.
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objeCtives: Thyroid function testing during amiodarone therapy is recommended 
every 6 months in order to control for the risk of hypothyroidism and thyrotoxicity, 
although evidence of the effect of regular monitoring on the risk of amiodarone-
related ADEs, cost and utility is sparse. This study investigated the cost-effectiveness 
of alternative frequency of monitoring amiodarone therapy in UK general prac-
tice. Methods: A cost-effectiveness analysis compared alterative frequency of 
monitoring (once in 6 months (recommended frequency), less than once in 6 months 
(less frequent), more than once in 6 months (more frequent)). A Markov model with 
cycle length of 90 days and 5 year horizon simulated progression through the ADE 
pathway (hypothyroidism, thyrotoxicity, cardiac complications). Treatment effect 
of monitoring on risk of ADE was estimated from UK GP and hospital observational 
data. Propensity score weights were used to control for non-random assignment. 
Probabilities, utilities and costs were derived from literature on amiodarone-related 
toxicity, with priority given to UK based-studies. Cost and utility was assessed from 
the perspective of NHS England and discounted at 3.5% per annum. A probabil-
istic sensitivity analysis (PSA) estimated the effect of parametric uncertainty on 
incremental cost and effect. Results: Recommended frequency monitoring was 
the dominant strategy. Mean incremental QALYs: 0.036 (95%CI -0.066,0.075), 0.039 
(-0.068,0.085); mean additional cost: -£6 (-283,272), -£61 (-360,238) vs. less frequent 
and more frequent monitoring, respectively. However, due to small differences in 
QALY and cost generated and significant uncertainty in model parameters, the prob-
ability of cost-effectiveness was 41% at £20,000/QALY threshold. ConClusions: 
The analysis supported the current recommendation for 6-monthly monitoring of 
thyroid function in amiodarone therapy, although the confidence in this conclusion 
was low due to poor evidence on the risk of amiodarone-related thyroid ADEs and 
their economic effect. Additional investigation of amiodarone monitoring is needed 
in order to justify its application in primary care.
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objeCtives: This study estimated the cost-effectiveness of novel oral anticoagu-
lants for (i) acute treatment and (ii) secondary prevention, of VTE from the perspec-
tive of the NHS. Methods: Secondary prevention:A Markov model was developed 
to evaluate cost-effectiveness of aspirin, rivaroxaban, dabigatran, warfarin (INR 2-3), 
apixaban 2.5mg and apixaban 5mg, compared to “no pharmacotherapy”. Acute treat-
ment: A decision tree model for short term outcomes, followed by the secondary pre-
vention model for long-term consequences, was used to evaluate cost-effectiveness 
of dabigatran, rivaroxaban, apixaban and edoxaban, compared with warfarin (INR 
2-3). All interventions were considered at the licensed dose(s). Efficacy and safety 
parameters were informed by network meta-analyses and longitudinal studies were 
used to parameterise the long term follow up. The models had a life time horizon 
with costs and QALYs discounted at 3.5%. Results: All results are presented at a 
£20,000 willingness to pay per QALY threshold Acute treatment:Apixaban showed 
the highest expected QALYs (12.02) and was the most cost-effective intervention 
with an incremental net monetary benefit of £645 (£-1,274 to £2,100) compared to 
Warfarin. Rivaroxaban also had a positive incremental net benefit (£167); all other 
comparators had a negative incremental net monetary benefit compared with war-
farin. Secondary prevention:Although aspirin has a higher risk of recurrent VTE 
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objeCtives: To identify published cost-effectiveness analyses and health technol-
ogy assessment (HTA) submissions for treatments in chronic heart failure (CHF) to 
inform future cost-effectiveness modeling in CHF. Methods: A systematic review 
was performed. Literature searches were conducted in MEDLINE, EMBASE, EconLit, 
and the Cochrane Library, with supplementary hand searching of conferences and 
HTA websites. Eligible studies had to report on cost-effectiveness outcomes in 
adults with CHF and/or heart failure with reduced ejection fraction, treated with 
angiotensin-converting enzyme inhibitors, beta-blockers, mineralocorticoid recep-
tor antagonists, angiotensin receptor blockers, or ivabradine. Results: Sixty-six 
publications met the inclusion criteria, representing 63 distinct analyses. Of these, 
53 reported their Methods: 20 were statistical analyses of individual patient 
data, while 33 used decision-analytic modeling. Structures were most commonly 
described as being Markov (n= 27) but the methods were heterogeneous. The health 
states most frequently employed were ‘alive’ or ‘dead’, with outcomes such as hos-
pitalization or New York Heart Association (NYHA) class distribution most com-
monly considered as a partition of the ‘alive’ state. Other health states considered 
were often based on NYHA class, hospitalizations, and major CV events. Different 
approaches to modeling the effects of interventions on mortality were used; treat-
ment effects were applied to cardiovascular (CV) mortality and all-cause mortality 
in nine and 20 studies (among the 33 decision-analytic models), respectively. Across 
included studies, the time horizon ranged from within-trial to lifetime. Outcomes 
were frequently sensitive to baseline risks of mortality and hospitalization, rela-
tive efficacy of interventions, and unit costs of interventions. ConClusions: The 
studies identified were heterogeneous with respect to their approaches; this may 
be due to the preference of payers in different jurisdictions. However, the identified 
literature suggests mortality and hospitalization are the key determinants of the 
cost-effectiveness of treatment for CHF.
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objeCtives: Bleeding during complex cardiac surgery is associated with several 
negative clinical outcomes. Fibrinogen concentrate (FC) is a coagulation factor 
concentrate that may positively affect these clinical outcomes. The objective of 
this study was to compare health economic outcomes between using a hemostatic 
therapy protocol with FC and a protocol without FC during complex cardiac sur-
gery. Methods: The input data of the model was based on a systematic literature 
search, and interviews with experts. Costs were retrieved from national databases. 
The primary effectiveness parameters were the number of blood transfusions 
avoided and the amount of blood loss avoided. One-way and probabilistic sensitiv-
ity analyses (PSA) were performed to test the robustness of results. Results: Five 
studies were included, representing 143 patients. The incremental costs per blood 
transfusion avoided were € 63 and per unit blood loss avoided € 2.4. The average 
number of blood transfusions reduced with 10 units per patient [95% CI: 8 - 12] and 
blood loss with 391mL/12hrs [95%CI: 81mL/12hrs – 711mL/12hrs] in the with FC 
protocol compared to the without FC protocol, whilst costs slightly increased (+€ 611 
[95%CI: € -2,210 - € 3,399]). The FC protocol reduced the number of blood transfusions 
and blood loss in 100% of the simulations of the PSA, and reduced these clinical 
outcomes and costs in 33.3%. The FC dosage was the main cost driver in the model. 
The FC protocol would be cost-saving if lower FC dosages were used (e.g. 2 or 4 
grams instead of 6.4 grams), or if costs of side effects were included (transfusion 
related lung injury and renal failure). ConClusions: Our study indicates that a 
hemostatic therapy protocol with FC is cost-effective in complex cardiovascular 
surgery, leading to better clinical outcomes with minimal incremental costs. Future 
studies need to provide clinical evidence that a lower dosage of FC will still suffice 
to ensure similar health outcomes.
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objeCtives: Determine the most cost-effective, licensed, first-line anticoagulant 
for the prevention of ischemic stroke in patients with non-valvular atrial fibril-
lation (AF) in England and Wales from the perspective of the UK National Health 
Service. Methods: We developed a cost-effectiveness model based on a review of 
previous models and expert clinical opinion. We compared warfarin (International 
Normalized Ratio 2-3) with novel oral anticoagulants (NOACs) apixaban (5mg bd), 
dabigatran (150mg bd), edoxaban (60mg od) and rivaroxaban (20mg od), over 30 
years post treatment initiation. Parameters were informed by a systematic litera-
ture review and competing risks network meta-analysis for comparative efficacy 
and safety of the anticoagulants and baseline hazard of warfarin. Utilities and 
resource use were estimated from the literature. Our model estimated total costs, 
Quality Adjusted Life Years (QALYs), and incremental net benefit relative to war-
farin. Results: At a willingness-to-pay threshold of £20,000 per QALY, all NOACs 
have positive expected incremental net benefit compared to warfarin, suggest-
ing they may be a cost effective use of NHS resources. Apixaban (5mg bd) has the 
highest expected incremental net benefit (£7533), followed by rivaroxaban (£6365), 
edoxaban (£5279) and dabigatran (£5279). Apixaban is the only NOAC for which 
the 95% credible interval around incremental net benefit is positive, suggesting 
a higher degree of certainty that Apixaban is cost-effective compared with war-
farin than for the other NOACs. These conclusions also hold at the higher thresh-
transition probabilities. We assigned costs and health outcomes to each health 
state to estimate the cost per quality-adjusted life year (QALY). Analyses were made 
from the National Health System (NHS) perspective, including direct healthcare 
costs (2015 euros) and a discount rate of 3% was applied to both costs and health 
outcomes. Time horizon was patient lifetime’s expectancy. We performed various 
sensitivity analyses, including probabilistic one, to assess the robustness of the 
results. Results: Compared to standard treatment, edoxaban was cost-effective 
using the different time horizons (3, 6 and 12 months). At 12 months, edoxaban 
showed a slight increment in treatment costs of 152€ per VTE patient, but an 
increase in QALYs and Life Years Gained (LYG) resulting in cost-effective results. 
Edoxaban demonstrated incremental cost-effectiveness ratios (ICERs) of 6,333 € 
per QALYs and 10,857 € per LYG compared with standard treatment at 12 months. 
The results of the probabilistic sensitivity analysis confirmed the efficiency of 
edoxaban. ConClusions: From the Spanish NHS perspective, edoxaban is a cost-
effective alternative for the treatment of VTE patients compared to standard therapy.
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objeCtives: Screening for atrial fibrillation (AF) has been advocated as a way to 
reduce the burden of stroke. Good quality evidence suggests that while oppor-
tunistic and systematic screening produce comparable increases in AF detection, 
opportunistic screening does so at significantly less cost. However, uncertainty 
about the risk profile of undiagnosed patients and the overall cost-effectiveness 
of screening has meant that no national AF screening programmes have as yet 
been implemented. The aim of this study was to evaluate the cost-effectiveness 
of a prospective national AF screening programme on stroke incidence and sever-
ity. Methods: We conducted a cost-utility analysis of opportunistic pulse palpation 
(with confirmatory ECG) in primary care in Ireland, comparing different start ages 
and screening frequencies. We also examined the implications of subclinical AF car-
rying a different risk of stroke than diagnosed AF, as well as the potential impact of 
increased use of new oral anticoagulant (NOACs) on the cost-effectiveness of screen-
ing. The primary analysis was conducted from the perspective of the publicly funded 
health system, using a time horizon of 25 years and a discount rate of 5% for costs 
and benefits. Results: Annual screening from age 65 is associated with an ICER of 
€ 20,271/QALY, with an 83% probability of being cost-effective at a willingness-to-pay 
threshold of € 45,000/QALY. Older start ages and longer screening intervals are likely 
to improve the cost-effectiveness of the intervention, but result in less absolute 
benefit. Annual screening from age 65 would not be cost-effective at a threshold 
of € 45,000/QALY if the relative risk of stroke and systemic embolism in subclinical 
AF is less than 0.84. Changes in usage rates of NOACs are unlikely to significantly 
affect the cost-effectiveness of screening. ConClusions: Opportunistic screening 
in primary care increases AF detection, reduces stroke incidence, and is likely to be 
cost-effective using conventional willingness-to-pay thresholds.
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objeCtives: To evaluate the cost-effectiveness of trimetazidine (TMZ) as add-on 
therapy to standard-of-care (SoC) compared to SoC alone in patients with chronic 
stable angina who did not respond adequately to first line therapy with beta-block-
ers, nitrates or calcium channel antagonists, in Greece. Methods: A Markov model 
with monthly cycles and 1-year time horizon was developed to assess the compara-
tors. The analysis was conducted from a third-party payer perspective. The clinical 
inputs and utility values were extracted from the published literature. Cost inputs 
considered in the model include anti-anginal drug-acquisition costs, hospitalization 
costs (with and without vascular interventions), and monitoring costs that encom-
pass outpatient visits, laboratory and diagnostic tests. Resource consumption data 
were obtained from local experts, using a questionnaire developed for the purpose 
of the study. These were combined with unit cost data obtained from official sources. 
All costs reflect the year 2014. Cost effectiveness was assessed by calculating the 
incremental cost effectiveness ratio (ICER). Probabilistic sensitivity analysis (PSA) 
was performed to account for uncertainty and variation in the input parameters of 
the model. Results: The analysis showed that the cost of TMZ plus SoC was € 1,055 
versus € 1,040 for SoC alone. In terms of health outcomes, TMZ plus SoC was associ-
ated with 0.617 QALYs versus 0.614 QALYs for SoC alone. The incremental analysis 
resulted in an ICER of € 4,148 per QALY gained. PSA revealed that the probability of 
TMZ plus SoC being cost-effective compared with SoC was 95%, at a threshold of 
€ 34,000 per QALY gained (twice the average annual income). ConClusions: The 
results indicate that TMZ as add–on treatment is a highly cost-effective option for 
the symptomatic treatment of patients with chronic stable angina in Greece when 
compared to SoC alone.
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